Nika Beamon set out on a journey, and 26 doctors, 37 procedures and more than 17 years later, a rheumatologist finally ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

However, some aspects are now better understood. AIP has two forms of involvement: Type 1 AIP, linked to immunoglobulin G4–related disease (IgG4-RD), and type 2 AIP, primarily associated with ...

For patients with IgG4-related disease, there are no approved therapies. New research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19 ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...